GlassScriptPhysician profile
Sean Duffy
NPI 1487215794
$4,774.68
in general payments reported to CMS, 2019-2025
30 companies · $1,870 in 2025
The $1,870 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $258 · 2023: $1,080 · 2024: $1,395 · 2025: $1,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,345.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $887.21 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $646.25 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Abbvie INC. | $476.43 | 2021-2025 | Ubrelvy |
| Lilly USA, LLC | $309.91 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.97 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $288.43 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $253.17 | 2021-2025 | Gardasil 9, Capvaxive, Verquvo |
| Exact Sciences Corporation | $211.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $184.66 | 2021-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $158.36 | 2024-2025 | |
| Glaxosmithkline, LLC. | $145.17 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.26 | 2022-2025 | Xifaxan |
| Boston Scientific Corporation | $95.60 | 2024-2025 | Wavewriter Alpha Prime 16, Watchman Access System |
| Amgen INC. | $90.80 | 2021-2025 | Repatha |
| Medtronic, INC. | $88.42 | 2022-2023 | Inpen Smart Insulin Delivery System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $68.21 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $62.94 | 2024-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $62.14 | 2022-2023 | |
| Seqirus USA INC | $59.28 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Xeris Pharmaceuticals, INC. | $52.76 | 2023-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $32.64 | 2024 | Korlym |
| Alexion Pharmaceuticals, INC. | $30.48 | 2025 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $26.88 | 2021-2023 | Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $24.05 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $22.38 | 2025 | Uptravi, Opsumit |
| Sanofi US Services INC. | $19.79 | 2024 | |
| Idorsia Pharmaceuticals US INC | $18.56 | 2022 | |
| Azurity Pharmaceuticals, INC. | $18.52 | 2024 | Horizant |
| Phathom Pharmaceuticals, INC. | $13.20 | 2024 | Voquezna |
| Acarix USA INC. | $12.78 | 2023 | Cadscor System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Duffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.